Comorbidity of opioid-related and anxiety-related symptoms and disorders

被引:26
|
作者
Langdon, Kirsten J. [1 ,2 ]
Dove, Kathrine [3 ]
Ramsey, Susan [2 ,4 ,5 ]
机构
[1] Rhode Isl Hosp, Dept Psychiat, Providence, RI 02903 USA
[2] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA
[3] Stonehill Coll, N Easton, MA USA
[4] Rhode Isl Hosp, Div Gen Internal Med, Providence, RI 02903 USA
[5] Brown Univ, Alpert Med Sch, Dept Med, Providence, RI 02912 USA
关键词
BUPRENORPHINE MAINTENANCE TREATMENT; COGNITIVE-BEHAVIORAL THERAPY; DISTRESS TOLERANCE; COMMITMENT THERAPY; BENZODIAZEPINE USE; PRESCRIPTION OPIOIDS; OVERDOSE DEATHS; UNITED-STATES; CHRONIC PAIN; SENSITIVITY;
D O I
10.1016/j.copsyc.2018.12.020
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Opioid use disorder and anxiety disorders co-occur at strikingly high rates, and this comorbidity is marked by a more severe clinical presentation and poorer prognosis for treatment. Given the substantial morbidity and mortality associated with these two disorders, it is imperative to understand factors related to the high rates of co-occurrence in order to inform the development of specialized treatments for this population. Several lines of study suggest that simultaneously addressing opioid-related and anxiety-related symptoms and processes, particularly intolerance of distress and pain-related anxiety, may yield improved outcomes for this high risk, vulnerable population. Future work is needed to identify other novel mechanisms as well as develop specialized treatments to augment standard medication-assisted treatment.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 50 条
  • [1] Mechanisms of comorbidity, continuity, and discontinuity in anxiety-related disorders
    McNaughton, Neil
    Corr, Philip J.
    [J]. DEVELOPMENT AND PSYCHOPATHOLOGY, 2016, 28 (04) : 1053 - 1069
  • [2] Anxiety-related disorders: An overview
    Riordan, Denise M.
    Singhal, Deepa
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2018, 54 (10) : 1104 - 1109
  • [3] Use of cannabidiol in anxiety and anxiety-related disorders
    Skelley, Jessica W.
    Deas, Crystal M.
    Curren, Zachary
    Ennis, Jonathan
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (01) : 253 - 261
  • [4] Anxiety-Related Disorders in the Context of Racism
    MacIntyre, M. Myriah
    Zare, Manzar
    Williams, Monnica T.
    [J]. CURRENT PSYCHIATRY REPORTS, 2023, 25 (02) : 31 - 43
  • [5] The cerebellum in fear and anxiety-related disorders
    Moreno-Rius, Josep
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2018, 85 : 23 - 32
  • [6] Update on treatments for anxiety-related disorders
    Lee, Hyun Jeong
    Stein, Murray B.
    [J]. CURRENT OPINION IN PSYCHIATRY, 2023, 36 (02) : 140 - 145
  • [7] Introduction - Remission of anxiety-related disorders
    Shelton, RC
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 : 3 - 4
  • [8] Inhibitory Learning for Anxiety-Related Disorders
    Tolin, David F.
    [J]. COGNITIVE AND BEHAVIORAL PRACTICE, 2019, 26 (01) : 225 - 236
  • [9] Anxiety-Related Disorders in the Context of Racism
    M. Myriah MacIntyre
    Manzar Zare
    Monnica T. Williams
    [J]. Current Psychiatry Reports, 2023, 25 : 31 - 43
  • [10] Covid-19, anxiety, and anxiety-related disorders
    Fullana, Miquel A.
    Littarelli, Sergio A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 51 : 87 - 89